Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 14 December 2019

Abstract and Keywords

This chapter describes the startlingly good outcomes associated with bariatric surgery, such as rapid improvement or even resolution of high blood pressure and Type II diabetes in almost all patients, and decreased mortality relative to a control group that is morbidly obese but did not get surgery. There are two main types of prescription drugs approved by the U.S. Food and Drug Administration for treating obesity: appetite suppressants and lipase inhibitors. There is significant weight loss under bariatric surgery, which results in much more weight loss and reduction in co-morbidities (e.g., diabetes) and mortality than bariatric medications. The potential move to endoscopically placed gastric devices is based on research which shows that many of the benefits of gastric bypass, such as immediate mitigation of diabetes, is due to a change in gut peptide release, not a reduction in food intake.

Keywords: bariatric surgery, high blood pressure, Type II diabetes, mortality, obesity, appetite suppressants, lipase inhibitors

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.